Global cannabis net revenue of $60.6 Million Adjusted EBITDA improved by 22% to a loss of $9.0 Million versus Q1 2022 Company reaffirms goal of adjusted EBITDA profitability by H1/2023 Transformation plan ahead of schedule; company now expects to realize upper end of $60 to $80 Million range in total cost savings by H1/2023; ~$60 million annualized savings implemented to date Company remains #1 Canadian LP in global medical cannabis; international cannabis revenue increased 24% from Q1 2022
I just listened to the cc again. The plan is working, the new brands coming out this spring are based off their brand which is both profitable and growing. 80m vs 60m is huge. I think we end green tomorrow. Guess we find out soon!